Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The trial followed 54 healthy adults over six months, dividing them into a placebo group, a low-dose group (250 mg/day), and a high-dose group (1000 mg/day), meticulously tracking glutathione levels across multiple cellular compartments, as detailed in the published clinical trial
The above studies suggest that the hepatoprotective activity of salvianolic acid B against APAP is achieved by inhibiting cytochrome P450 enzymes and/or synergizing phase II metabolic enzymes
Z., Kipps, T
No evidence of serious hormonal, hepatic, or systemic adverse effects has been observed in available data
ALA IV Therapy is also used in metabolic cancer care and neuropathies
US$ 28.02
US$ 21.36
US$ 21.97
US$ 22.32
